



HFV

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/812,619
	Filing Date	30 March 2004
	First Named Inventor	Po-Ying CHAN-HUI
	Art Unit	Not Yet Assigned
	Examiner Name	Not Yet Assigned
Total Number of Pages in This Submission	Attorney Docket Number	131.02US

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Technology Center (TC) <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input type="checkbox"/> Other Enclosure(s) (please identify below): 1. Copies of cited references. 2. Return Receipt Postcard
<div>Remarks</div>		
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT		
Firm or Individual name	Stephen C. Macevicz, Registration No. 30,285	
Signature		
Date	11 June 2004	

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.			
Typed or printed name	Virginia Griffith		
Signature		Date	11 June 2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as first class mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this date.

Typed or printed name: Virginia Griffith

Date: 11 June 2004

Signature:

Virginia Griffith

Case No. 131.02US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

First Named Inventor: Po-Ying CHAN-HUI.

Serial No: 10/812,619

Customer No. 33,603

Filed: 30 March 2004

Examiner: Not Yet Assigned

For: SURFACE RECEPTOR
COMPLEXES AS BIOMARKERS

Art Unit: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The references cited on the accompanying PTO-1449 form(s) may be material to the examination of the above-identified application and are, therefore, submitted in compliance with the duty of disclosure defined in 37 CFR 1.56 and 1.97. The Examiner is requested to make these citations of official record in this application. Copies of the cited references are enclosed or have been previously submitted in prior application(s) to the above application.

This Information Disclosure Statement under 37 CFR 1.56 and 1.97 is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one or more of these citations constitutes prior art.

SUBMISSION INFORMATION

This Information Disclosure Statement is being submitted within three (3) months of filing or before mailing of a first Office Action, whichever occurs last. (37 CFR 1.97(b))


PAYMENT OF FEES (IF ANY DUE)

FEE AUTHORIZATION. The Commissioner is hereby authorized to withdraw from Deposit Account

50-2266

any submission fees or petition fees required for this Information Disclosure Statement.

Respectfully submitted,



Stephen C. Macevicz
Registration No. 30,285
(650) 210-1223 Direct Telephone
*650) 210-5959 Facsimile

Enclosures:
PTO Form 1449 w/copies of cited references

Form PTO-1449 (adapted) REFERENCES CITED BY APPLICANT	Docket No. 131.02US	Serial No. 10/812,619
	First Named Inventor Po-Ying CHAN-HUI	Customer No. 33603
	Filing Date 30 March 2004	Group Not Yet Assigned

References below marked with (*) have been submitted with parent application Ser. No. 10/154,042.
 References below marked with (^) have been submitted with parent application Ser. No. 10/623,057.

U.S. PATENT DOCUMENTS

Examiner's Initial		Document Number	Inventor(s)	Issue Date (publication date) (mm dd yyyy)	Class/Subclass	Filing Date (mm dd yyyy)
	P1	2002/0037542	ALLBRITTON	(03/28/2002)	435/7.23	05/17/2001
	P2	4,331,590	BOCUSLASKI	05/25/1982	260/112 B	05/06/1980
	P3	4,650,750	GIESE	03/17/1987	435/7	03/19/1984
	P4	4,709,016	GIESE	11/24/1987	530/389	02/01/1982
	P5	4,780,421	KAMEDA	10/25/1988	436/518	04/03/1986
	P6	5,057,412	RABIN	10/15/1991	435/6	03/15/1988
	P7	5,340,716	ULLMAN	08/23/1994	435/6	06/20/1991
	P8	5,360,819	GIESE	11/01/1994	514/538	03/11/1985
	P9	5,470,705	GROSSMAN	11/28/1995	435/6	04/07/1992
	P10	5,494,793	SCHINDELE	02/27/1996	435/6	06/14/1989
	P11	5,514,543	GROSSMAN	05/07/1996	435/6	08/04/1993
	P12	5,516,636	MCCAPRA	05/14/1996	435/6	12/01/1992
	P13	5,516,931	GIESE	05/14/1996	560/59	04/22/1993
	P14	5,536,834	SINGH	07/16/1996	544/98	06/06/1995
	P15	5,565,324	STILL	10/15/1996	435/6	04/13/1994
	P16	5,578,498	SINGH	11/26/1996	436/518	11/22/1993
	P17	5,580,732	GROSSMAN	12/03/1996	435/6	08/26/1994
	P18	5,602,273	GIESE	02/11/1997	560/60	02/08/1996
	P19	5,604,104	GIESE	02/18/1997	435/7.1	02/08/1996

EXAMINER	Date considered
*EXAMINER: Initial if reference considered, whether or not citation in conformance with MPEP 609; Draw line through citation if not in conformance and/or not considered. Include copy of this form with next communication to applicant.	

Form PTO-1449 (adapted) REFERENCES CITED BY APPLICANT	Docket No. 131.02US	Serial No. 10/812,619
	First Named Inventor Po-Ying CHAN-HUI	Customer No. 33603
	Filing Date 30 March 2004	Group Not Yet Assigned

References below marked with (*) have been submitted with parent application Ser. No. 10/154,042.

References below marked with (^) have been submitted with parent application Ser. No. 10/623,057.

	P20	5,610,020	GIESE	03/11/1997	435/7.1	02/08/1996
	P21	5,616,719	DAVALIAN	04/01/1997	546/334	05/09/1995
	P22	5,624,800	GROSSMAN	04/29/1997	435/6	05/19/1995
	P23	5,650,270	GIESE	07/22/1997	435/6	03/20/1990
	P24	5,703,222	GROSSMAN	12/30/1997	536/24.3	11/21/1995
	P25	5,705,622	McCAPRA	01/06/1998	536/23.1	03/28/1996
	P26	5,709,994	PEASE	01/20/1998	435/4	06/06/1995
	P27	5,721,099	STILL	02/24/1998	435/6	06/07/1995
	P28	5,756,726	HEMMI	05/26/1998	540/474	06/06/1995
	P29	5,766,481	ZAMBIAS	06/16/1998	210/656	02/18/1997
	P30	5,777,096	GROSSMAN	07/07/1998	536/24.3	05/06/1996
	P31	5,789,172	STILL	08/04/1998	435/6	07/11/1996
	P32	5,807,675	DAVALIAN	09/15/1998	435/6	06/07/1995
	P33	5,807,682	GROSSMAN	09/15/1988	435/6	06/17/1997
	P34	5,843,655	McGALL	12/01/1998	435/6	09/18/1995
	P35	5,843,666	AKHAVAN-TAFTI	12/01/1998	435/6	11/15/1996
	P36	5,846,839	GALLOP	12/08/1998	436/518	12/22/1995
	P37	5,849,878	CANTOR	12/15/1998	530/391.9	06/07/1995
	P38	5,952,654	GIESE	09/14/1999	250/288	10/29/1997
	P39	5,958,202	REGNIER	09/28/1999	204/451	01/22/1997
	P40	5,986,076	ROTHSCHILD	11/16/1999	536/22.1	11/22/1994

EXAMINER	Date considered
*EXAMINER: Initial if reference considered, whether or not citation in conformance with MPEP 609; Draw line through citation if not in conformance and/or not considered. Include copy of this form with next communication to applicant.	

Form PTO-1449 (adapted) REFERENCES CITED BY APPLICANT	Docket No. 131.02US	Serial No. 10/812,619
	First Named Inventor Po-Ying CHAN-HUI	Customer No. 33603
	Filing Date 30 March 2004	Group Not Yet Assigned

References below marked with (*) have been submitted with parent application Ser. No. 10/154,042.

References below marked with (^) have been submitted with parent application Ser. No. 10/623,057.

	P41	5,989,871	GROSSMAN	11/23/1999	435/91.1	02/14/1997
	P42	6,001,579	STILL	12/14/1999	435/7.1	06/07/1995
	P43	6,027,890	NESS	02/22/2000	435/6	07/22/1997
	P44	6,251,581	ULLMAN	06/26/2001	435/4	05/22/1991
	P46	6,312,893	VAN NESS	11/06/2001	435/6	07/22/1997
	P47	6,322,980	SINGH	11/27/2001	435/6	04/30/1999
	P48	6,331,530	BRESLOW	12/18/2001	514/58	07/13/1999
	P49	6,335,201	ALLBRITTON	01/01/2002	436/63	07/21/1999
	P50	6,346,384	POLLNER	02/12/02	435/6	03/27/00
	P51	6,346,529	FLOYD	02/12/2002	514/226.2	04/15/1998
	P52	6,368,874	GALLOP	04/09/2002	436/518	11/17/1999
	P53	5,646,001	TERSTAPPEN	07/08/97	435/7.21	02/28/95
	P54	6,365,362	TERSTAPPEN	04/04/04	435/7.23	02/12/99

ADDITIONAL U.S. PATENT DOCUMENTS

Examiner's Initial		Document Number	Inventor(s)	Class /Subclass	Title	Issue Date or Publ. Date (dd.mm.yy)
	PP1	2004/0018528	Morimoto	435/006	Novel biomarkers of tyrosine kinase inhibitor exposure and activity in mammals	29 Jan 04
	PP2	2003/0170734	Williams	435/7.1	Multiplexed assays using electrophoretically separated molecular tags	01 Apr 03
	PP3	2003/0207403	Paszyty	435/69.1	Beta-like glycoprotein hormone polypeptide and heterodimer	06 Nov 03

EXAMINER	Date considered
*EXAMINER: Initial if reference considered, whether or not citation in conformance with MPEP 609; Draw line through citation if not in conformance and/or not considered. Include copy of this form with next communication to applicant.	

REFERENCES CITED BY APPLICANT	Docket No. 131.02US	Serial No. 10/812,619
	First Named Inventor Po-Ying CHAN-HUI	Customer No. 33603
	Filing Date 30 March 2004	Group Not Yet Assigned

References below marked with (*) have been submitted with parent application Ser. No. 10/154,042.

References below marked with (^) have been submitted with parent application Ser. No. 10/623,057.

	PP4	2003/0190689	Crosby	435/7.23	Molecular profiling of disease and therapeutic response using phospho-specific antibodies	09 Oct 03
	PP5	2002/0172984	Holland	435/7.21	Oligomerized receptors which affect pathways regulated by transmembrane ligands for Elk-related receptor tyrosine kinases	21 Nov 02
	PP6	2004/0033542	Frackelton	435/7.23	Shc protein-related methods and compositions for the prognosis of breast, prostate and ovarian cancer	19 Feb 04
	PP7	2004/0023288	Ridder	435/6	Method for solution based diagnosis	05 Feb 04
	PP8	2004/0029194	Parish	435/7.23	Method of identifying cancer markers and uses therefor in the diagnosis of cancer	12 Feb 04
	PP9	2004/0018562	Rouhani	435/7.1	Receptor detection	29 Jan 04
	PP10	Re. 35,491	Cline	435/6	Methods and compositions for detecting human tumors	08 Apr 97
	PP11	5,968,511	Akita	424/141.1	ERBB3 Anitbodies	19 Oct 99
	PP12	5,480,968	Kraus	530/326	Isolated Polypeptide ErbB-3, Related to the Epidermal Growth Factor Receptor and Antibody thereto	02 Jan 96
	PP13	5,874,542	Rockwell	530/387.3	Single Chain Antibodies Specific to VEGF Receptors	23 Feb 99
	PP14	6,383,740	Collins	435/5	Methods for Simultaneously Detecting Both Members of a Binding Pair	07 May 02
	PP15	6,358,682	Jaffee	435/6	Method and Kit for the Prognostication of Breast Cancer	19 Mar 02
	PP16	5,192,660	Reed-Gitomer	435/7.21	Elisa Methods for the Determination of Human Platelet Derived Growth Factor (PDGF) Dimer Forms Present in Human Tissues and Fluids	09 May 93
	PP17	6,388,063	Plowman	536/23.5	Diagnosis and Treatment of SAD Related Disorders	14 May 02
	PP18	4,968,603	Slamon	435/6	Determination of Status in Neoplastic Disease	06 Nov 90
	PP19	4,772,550	Greenquist	435/7	Heterogeneous Specific Binding Assay Employing an Aggregatable Binding Reagent	20 Sep 88
	PP20	4,891,324	Pease	436/519	Particle with luminescer for assays	02 Jan 90

EXAMINER	Date considered
<p>*EXAMINER: Initial if reference considered, whether or not citation in conformance with MPEP 609; Draw line through citation if not in conformance and/or not considered. Include copy of this form with next communication to applicant.</p>	

Form PTO-1449 (adapted)	Docket No. 131.02US	Serial No. 10/812,619
REFERENCES CITED BY APPLICANT	First Named Inventor Po-Ying CHAN-HUI	Customer No. 33603
	Filing Date 30 March 2004	Group Not Yet Assigned

References below marked with (*) have been submitted with parent application Ser. No. 10/154,042.

References below marked with (^) have been submitted with parent application Ser. No. 10/623,057.

	PP21	5,804,396	Plowman	435/7.23	Assay for Agents Active in Proliferative Disorders	08 Sep 98
	PP22	5,108,896	Philo	435/7.5	Simultaneous Immunoassay of Two Analytes Using Dual Enzyme Labelled Antibodies	28 Apr 92
	PP23	5,436,128	Harpold	435/6	Assay Methods and Compositions for Detecting and Evaluating the Intracellular Transduction of an Extracellular Signal	25 Jul 95
	PP24	5,800,999	Bronstein	435/6	Dioxetane-precursor-labeled probes and detection assays employing the same	01 Sep 98
	PP25	5,886,238	Schaap	568/650	Alkene precursors for preparing chemiluminescent dialkyl-substituted 1,2-dioxetane compounds	23 Mar 99
	PP26	6,001,573	Roelant	435/6	Use of porphyrins as a universal label	14 Dec 99
	PP27	6,727,072	Spaulding	435/7.21	EGF-R Detection Kit	27 Apr 04
	PP28	6,489,116	Wagner	435/6	Sensitive, Multiplexed Diagnostic Assays for Protein Analysis	03 Dec 02
	PP29	6,248,546	Khosravi	435/7.94	Assay of IGFBP Complex	19 Jun 01
	PP30	6,627,400	Singh	435/6	Multiplexed Measurement of Membrane Protein Populations	30 Sep 03
	PP31	6,417,168	Greene	514/44	Compositions and Methods of Treating Tumors	09 Jul 02
	PP32	6,573,043	Cohen	435/6	Tissue Analysis and Kits therefor	03 Jun 03
	PP33	6,627,196	Baughman	424/138.1	Dosages for Treatment with Anti-ErbB2 Antibodies	30 Sep 03

FOREIGN PATENT DOCUMENTS

Examiner's Initial		Country	Document Number	Applicant	Date (mm-dd-yyyy)
	F1*	EP	0 484 027	IMPERIAL CHEMICAL INDUSTRIES PLC	05/06/1992
	F2*	WO	93/06121	AFFYMAX TECHNOLOGIES N.V.	04/01/1993
	F3*	WO	96/24061	ONTOGEN CORPORATION	08/08/1996

EXAMINER	Date considered
*EXAMINER: Initial if reference considered, whether or not citation in conformance with MPEP 609; Draw line through citation if not in conformance and/or not considered. Include copy of this form with next communication to applicant.	

REFERENCES CITED BY APPLICANT	Form PTO-1449 (adapted)	Docket No. 131.02US	Serial No. 10/812,619
		First Named Inventor Po-Ying CHAN-HUI	Customer No. 33603
		Filing Date 30 March 2004	Group Not Yet Assigned

References below marked with (*) have been submitted with parent application Ser. No. 10/154,042.

References below marked with (^) have been submitted with parent application Ser. No. 10/623,057.

	F4*	WO	97/27325	DARWIN MOLECULAR CORPORATION	07/31/1997
	F5*	WO	97/27327	DARWIN MOLECULAR CORPORATION	07/31/1997
	F6*	WO	97/28275	IGEN INTERNATIONAL INC.	08/07/1997
	F7*	WO	98/01533	BURSTEIN LABORATORIES, INC.	01/15/1998
	F8*	WO	98/15830	WALLAC OY	04/16/1998
	F9*	WO	99/05319	RAPIGENE, INC.	02/04/1999
	F10*	WO	99/42838	DADE BEHRING INC.	08/26/1999
	F11*	WO	99/64519	AMERSHAM PHARMACIA BIOTECH UK LIMITED	12/16/1999
	F12*	WO	00/56925	ACLARA BIOSCIENCES, INC.	09/28/2000
	F13*	WO	00/66607	ACLARA BIOSCIENCES, INC.	11/09/2000

ADDITIONAL FOREIGN PATENT DOCUMENTS

Examiner's Initial		Country and Document Number	Inventor	Title	Publication Date (dd-mm-yy)
	FF1	WO 2004/008099	Koll	Methods for Identifying Tumors that are Responsive to Treatment with Anti-ErbB2 Antibodies	22 Jan 04
	FF2	WO 2004/000102	Bacus	Method for Predicting Response to Epidermal Growth Factor Receptor-Directed Therapy	31 Dec 03
	FF3	WO 01/57530	Liotta	Method and Apparatus for Signal Transduction Pathway Profiling	09 Aug 01
	FF4	WO 93/06121	Dower	Method of Synthesizing Diverse Collections of Oligomers	01 Apr 93
	FF5	WO 97/00446	Landegren	Immunoassay and Kit with Two Reagents That Are Cross-Linked If They Adhere To an Analyte	03 Jan 97
	FF6	WO 98/42736	Hochstrasser	Diagnosis of Colorectal Cancer and Proteins and Antibodies for Use therein	01 Oct 98

EXAMINER	Date considered
*EXAMINER: Initial if reference considered, whether or not citation in conformance with MPEP 609; Draw line through citation if not in conformance and/or not considered. Include copy of this form with next communication to applicant.	

Form PTO-1449 (adapted)	Docket No. 131.02US	Serial No. 10/812,619
	First Named Inventor Po-Ying CHAN-HUI	Customer No. 33603
	Filing Date 30 March 2004	Group Not Yet Assigned

REFERENCES CITED BY APPLICANT

References below marked with (*) have been submitted with parent application Ser. No. 10/154,042.
References below marked with (^) have been submitted with parent application Ser. No. 10/623,057.

^	FF7	WO 99/42838	Singh	Chemiluminescent Compositions for Use in Detection of Multiple Analytes	26 Aug 99
	FF8	WO 03/045990	LeGrain	Protein-Protein Interactions Involving Transforming Growth Factor β Signaling or Involving Transduction Signals of Transforming Factor β Family Members	05 Jun 03
	FF9	WO 2004/009798	Rich	Protein Interaction Difference Mapping	29 Jan 04

OTHER REFERENCES

Examiner's Initial		Citation
	D1	Ady, et al., "Detection of HER-2/neu-positive circulating epithelial cells in prostate cancer patients", British Journal of Cancer, 2004, 90:443-448.
	D2	Agus, et al., "A Potential Role for Activated HER-2 in Prostate Cancer", Seminars in Oncology, 2000, 27:76-100.
	D3	Agus, et al., "Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth", Cancer Cell, 2002, 2:127-137.
	D4	Ahram, et al., "Proteomic Analysis of Human Prostate Cancer", Molecular Carcinogenesis, 2002, 33:9-15.
	D5	Albanell, et al., "Mechanism of Action of Anti-HER2 Monoclonal Antibodies: Scientific Update on Trastuzumab and 2C4", New Trends in Cancer for the 21 st Century, 2003, 253-268.
	D6	Alimandi, et al., "Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas", Oncogene, 1995, 10:1813-1821.
	D7	Andersen, "Determination of Estrogen Receptors in Paraffin-Embedded Tissue", Acta Oncologica, 1992, 31:611-627.
	D8	Angers, et al., "Dimerization: An Emerging Concept for G Protein-Coupled Receptor Ontogeny and Function", Annu. Rev. Pharmacol. Toxicol., 2002, 42:409-435.
	D9	Antonsson, et al., "An <i>in Vitro</i> 96-Well Plate Assay of the Mitogen-Activated Protein Kinase Cascade", Analytical Biochemistry, 1999, 267:294-299.
	D10	Arteaga, "Epidermal Growth Factor Receptor Dependence in Human Tumors: More Than Just Expression?", The Oncologist, 2002, 7:31-39.
	D11	Auerbach, et al., "Proteomic approaches for generating comprehensive protein interaction maps", Targets, 2003, 2:85-92.
	D12	Baselga, "Anti-EGFR therapy: A new targeted approach to cancer treatment", Oncology Biotherapeutics, 2002, 2:2-36.
	D13	Baselga, "A new anti-ErbB2 strategy in the treatment of cancer: Prevention of ligand-dependent ErbB2 receptor heterodimerization", Cancer Cell, 2002, 2:93-95.

EXAMINER	Date considered
*EXAMINER: Initial if reference considered, whether or not citation in conformance with MPEP 609; Draw line through citation if not in conformance and/or not considered. Include copy of this form with next communication to applicant.	

^ Don't Receive

Form PTO-1449 (adapted)	Docket No. 131.02US	Serial No. 10/812,619
REFERENCES CITED BY APPLICANT	First Named Inventor Po-Ying CHAN-HUI	Customer No. 33603
	Filing Date 30 March 2004	Group Not Yet Assigned

References below marked with (*) have been submitted with parent application Ser. No. 10/154,042.

References below marked with (^) have been submitted with parent application Ser. No. 10/623,057.

	D14	Baselga, et al., "Mechanism of action of anti-HER2 monoclonal antibodies", Annals of Oncology, 2001, 12:S35-S41.
	D15	Bast, et al., "Coexpression of the HER-2 Gene Product, p185 ^{HER-2} , and Epidermal Growth Factor Receptor, p170 ^{EGF-R} , on Epithelial Ovarian and Normal Tissues", Hybridoma, 1998, 17:313-321.
	D16^	Beaudet, et al., "Homogenous Assays for Single-Nucleotide Polymorphism Typing Using AlphaScreen", Genome Research, 2001, 11:600-608.
	D17	Becker, "Signal transduction inhibitors-a work in progress", Nature Biotechnology, 2004, 22:15-18.
	D18	Bei, et al., "Co-localization of multiple ErbB receptors in stratified epithelium of oral squamous cell carcinoma", Journal of Pathology, 2001, 195:343-348.
	D19	Bichsel, et al., "Cancer Proteomics: From Biomarker Discovery to Signal Pathway Profiling", The Cancer Journal, 2001, 7:69-78.
	D20	Blagoev, et al., "A proteomics strategy to elucidate functional protein-protein interactions applied to EGF signaling", Nature Biotechnology, 2003, 21:315-318.
	D21	Blakely, et al., "Epidermal growth factor receptor dimerization monitored in live cells", Nature Biotechnology, 2000, 18:218-222.
	D22	Blume-Jensen, et al., "Oncogenic kinase signalling", Nature, 2001, 411: 355-365.
	D23	Bodey, et al., "Clinical and Prognostic Significance of the Expression of the <i>c-erbB-2</i> and <i>c-erbB-3</i> Oncoproteins in Primary and Metastatic Malignant Melanomas and Breast Carcinomas", Anticancer Research, 1997, 17:1319-1330.
	D24	Bohula, et al., "Targeting the type 1 insulin-like growth factor receptor as anti-cancer treatment", Anti-Cancer Drugs, 2003, 14:669-682.
	D25	Brandt, et al., "c-erbB-2/EGFR as dominant heterodimerization partners determine a motogenic phenotype in human breast cancer cells", The FASEB Journal, 1999, 13:1939-1949.
	D26	Brockhoff, et al., "Epidermal Growth Factor Receptor, c-erbB2 and c-erbB3 Receptor Interaction, and Related Cell Cycle Kinetics of SK-BR-3 and BT474 Breast Carcinoma Cells", Cytometry, 2001, 44:338-348.
	D27	Chow, et al., "Expression profiles of ErbB Family Receptors and Prognosis in Primary Transitional Cell Carcinoma of the Urinary Bladder", Clinical Cancer Research, 2001, 7:1957-1962.
	D28	Clot, et al., "HLA-DR53 molecules are associated with susceptibility to celiac disease and selectively bind gliadin-derived peptides", Immunogenetics, 1999, 49:800-807.
	D29	Dahan, et al., "Diffusion Dynamics of Glycine Receptors Revealed by Single-Quantum Dot Tracking", Science, 2003, 302:442-446.
	D30	Dean, et al., "Cell Surface Density of p185 ^{c-erbB-2} Determines Susceptibility to Anti-P185 ^{c-erbB-2} Ricin A Chain (RTA) Immunotoxin Therapy Alone and in Combination with Anti-P170 ^{EGFR} RTA in Ovarian Cancer Cells", Clinical Cancer Research, 1998, 4:2545-2550.
	D31	DePrimo, et al., "Expression profiling of blood samples from an SU5416 Phase III metastatic colorectal cancer clinical trial: a novel strategy for biomarker identification", BMC Cancer, 2003, 3:1-12.
	D32	Dikic, "CIN85/CMS family of adaptor molecules", FEBS Letters, 2002, 529:110-115.

EXAMINER	Date considered
*EXAMINER: Initial if reference considered, whether or not citation in conformance with MPEP 609; Draw line through citation if not in conformance and/or not considered. Include copy of this form with next communication to applicant.	

REFERENCES CITED BY APPLICANT	Docket No. 131.02US	Serial No. 10/812,619
	First Named Inventor Po-Ying CHAN-HUI	Customer No. 33603
	Filing Date 30 March 2004	Group Not Yet Assigned

References below marked with (*) have been submitted with parent application Ser. No. 10/154,042.

References below marked with (^) have been submitted with parent application Ser. No. 10/623,057.

	D33	Fredriksson, et al., "Protein detection using proximity-dependent DNA ligation assays", <i>Nature Biotechnology</i> , 2002, 20:473-477.
	D34	Galarneau, et al., "β-Lactamase protein fragment complementation assays as <i>in vivo</i> and <i>in vitro</i> sensors of protein-protein interactions", <i>Nature Biotechnology</i> , 2002, 20:619-622.
	D35	Gamett, et al., "Secondary Dimerization between Memembers of the Epidermal Growth Factor Receptor Family", <i>The Journal of Biological Chemistry</i> , 1997, 272:12052-12056.
	D36	Gilbertson, et al., "ERBB Receptor Signaling Promotes Ependymoma Cell Proliferation and Represents a Potential Novel Therapeutic Target for This Disease", <i>Clinical Cancer Research</i> , 2002, 8:3054-3064.
	D37	Gilbertson, et al., "Expression of the ErbB-Neuregulin Signaling Network during Human Cerebellar Development: Implications for the Biology of Medulloblastoma", <i>Cancer Research</i> , 1998, 58:3932-3941.
	D38	Gilbertson, et al., "Prognostic Significance of HER2 and HER4 Coexpression in Childhood Medulloblastoma", <i>Cancer Research</i> , 1997, 57:3272-3280.
	D39	Graham, et al., "Application of β-Galactosidase Enzyme Complementation Technology as a High Throughput Screening format for Antagonists of the Epidermal Growth Factor Receptor", <i>Journal of Biomolecular Screening</i> , 2001, 6:401-411.
	D40	Graus-Porta, et al., "ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling", <i>The EMBO Journal</i> , 1997, 16:1647-1655.
	D41	Gur, et al., "Enlightened receptor dynamics", <i>Nature Biotechnology</i> , 2004, 22:169-170.
	D42	Hanash, "Disease Proteomics", <i>Nature</i> , 2003, 422:226-232.
	D43	Hanna, et al., "Evaluation of HER-2/neu (erbB-2) Status in Breast Cancer: From Bench to Bedside", <i>Mod. Pathol.</i> , 1999, 12:827-834.
	D44	Hayes, et al., "Monitoring expression of HER-2 on circulating epithelial cells in patients with advanced breast cancer", <i>International Journal of Oncology</i> , 2002, 21:1111-1117.
	D45	INTENTIONALLY LEFT BLANK
	D46	Herbst, et al., "Monoclonal Antibodies to Target Epidermal Growth Factor Receptor-Positive Tumors", <i>Cancer</i> , 2002, 94:1593-1611.
	D47	Holbro, et al., "The ErbB receptors and their role in cancer progression", <i>Experimental Cell Research</i> , 2003, 284:99-110.
	D48	Hondermarck, et al., "Proteomics of breast cancer for marker discovery and signal pathway profiling", <i>Proteomics</i> , 2001, 1:1216-1232.
	D49	Ibrahim, et al., "Epression of c-erbB Proto-Oncogene Family Memembers in Squamous Cell Carcinoma of the Head and Neck", <i>Anticancer Research</i> , 1997, 17:4539-4546.
	D50	Irvine, et al., "A colorimetric bead-binding assay for detection of intermolecular interactions", <i>Experimental Dermatology</i> , 2002, 11:462-467.
	D51	Jones, et al., "Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer", <i>Proteomics</i> , 2002, 2:76-84.

EXAMINER	Date considered
*EXAMINER: Initial if reference considered, whether or not citation in conformance with MPEP 609; Draw line through citation if not in conformance and/or not considered. Include copy of this form with next communication to applicant.	

Form PTO-1449 (adapted)	Docket No. 131.02US	Serial No. 10/812,619
	First Named Inventor Po-Ying CHAN-HUI	Customer No. 33603
	Filing Date 30 March 2004	Group Not Yet Assigned

REFERENCES CITED BY APPLICANT

References below marked with (*) have been submitted with parent application Ser. No. 10/154,042.

References below marked with (^) have been submitted with parent application Ser. No. 10/623,057.

	D52	Kanematsu, et al., "Phosphorylation, But Not Overexpression, of Epidermal Growth Factor Receptor Is Associated With Poor Prognosis of Non-Small Cell Lung Cancer Patients", <i>Oncology Research</i> , 2003, 13:289-298.
	D53	Karin, et al., "The IKK NF- κ B System: A Treasure Trove for Drug Development", <i>Nature Reviews Drug Discovery</i> , 2004, 3:17-26.
	D54	Karin, et al., "NF- κ B in Cancer: From Innocent Bystander to Major Culprit", <i>Nature Reviews Cancer</i> , 2002, 2:301-310.
	D55	Kolch, "Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interaction", <i>Biochem. J.</i> , 2000, 351:289-305.
	D56	Krähn, et al., "Coexpression patterns of <i>EGF</i> , <i>HER2</i> , <i>HER3</i> and <i>HER4</i> in non-melanoma skin cancer", <i>European Journal of Cancer</i> , 2001, 37:251-259.
	D57	Lee, et al., "Investigation of the prognostic value of coexpressed erbB family members for the survival of colorectal cancer patients after curative surgery", <i>European Journal of Cancer</i> , 2002, 38:1065-1071.
	D58	Li, et al., "NF- κ B Regulation in the Immune System", <i>Nature Reviews Immunology</i> , 2002, 2:725-735.
	D59	Lidke, et al., "Quantum dot ligands provide new insights into erbB/HER receptor-mediated signal transduction", <i>Nature Biotechnology</i> , 2004, 22:198-203.
	D60	Liotta, et al., "Molecular Profiling of Human Cancer", <i>Nature Reviews</i> , 2000, 1:48-56.
	D61	Lund-Johansen, et al., "Flow Cytometric Analysis of Immunoprecipitates: High-Throughput Analysis of Protein Phosphorylation and Protein-Protein Interactions", <i>Cytometry</i> , 2000, 39:250-259.
	D62	McDonald, et al., "Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease", <i>Nature Genetics</i> , 2001, 29:143-152; <i>Nature Genetics</i> , 2003, 35:287.
	D63	McDonald, et al., "A Scintillation Proximity Assay for the Raf/MEK/ERK Kinase Cascade: High-Throughput Screening and Identification of Selective Enzyme Inhibitors", <i>Analytical Biochemistry</i> , 1999, 268:318-329.
	D64	Madoz-Gurpide, et al., "Molecular Analysis of Cancer Using DNA and Protein Microarrays", <i>Advances in Experimental Medicine and Biology</i> , 2003, 532:51-58.
	D65	Mallon, et al., "An Enzyme-Linked Immunosorbent Assay for the Raf/MEK1/MAPK Signaling Cascade", <i>Analytical Biochemistry</i> , 2001, 294:48-54.
	D66	Matko, et al., "Energy Transfer Methods for Detecting Molecular Clusters on Cell Surfaces", <i>Methods in Enzymology</i> , 1997, 278:444-462.
	D67	Miller, et al., "Antibody microarray profiling of human prostate cancer sera: Antibody screening and identification of potential biomarkers", <i>Proteomics</i> , 2003, 3:56-63.
	D68	Muthuswamy, et al., "Controlled Dimerization of ErbB Receptors Provides Evidence for Differential Signaling by Homo- and Heterodimers", <i>Molecular Cell Biology</i> , 1999, 19:6845-6857.
	D69	Nagy, et al., "EGF-Induced Redistribution of erbB2 on Breast Tumor Cells: Flow and Image Cytometric Energy Transfer Measurements", <i>Cytometry</i> , 1998, 32:120-131.

EXAMINER	Date considered
*EXAMINER: Initial if reference considered, whether or not citation in conformance with MPEP 609; Draw line through citation if not in conformance and/or not considered. Include copy of this form with next communication to applicant.	

Form PTO-1449 (adapted) REFERENCES CITED BY APPLICANT	Docket No. 131.02US	Serial No. 10/812,619
	First Named Inventor Po-Ying CHAN-HUI	Customer No. 33603
	Filing Date 30 March 2004	Group Not Yet Assigned

References below marked with (*) have been submitted with parent application Ser. No. 10/154,042.

References below marked with (^) have been submitted with parent application Ser. No. 10/623,057.

	D70	Nahta, et al., "Growth Factor Receptors in Breast Cancer: Potential for Therapeutic Intervention", The Oncologist, 2003, 8:5-17.
	D71	Nam, et al., "Current Targets for Anticancer Drug Discovery", Current Drug Targets, 2003, 4:159-179.
	D72	Navolanic, et al., "EGFR family signaling and its association with breast cancer development and resistance to chemotherapy (Review)", International Journal of Oncology, 2003, 22:237-252.
	D73	Nicholson, et al., "The protein kinase B/Akt signalling pathway in human malignancy", Cellular Signalling, 2002, 14:381-395.
	D74	Olayioye, et al., "ErbB-1 and ErbB-2 Acquire Distinct Signaling Properties Dependent upon Their Dimerization Partner", Molecular and Cellular Biology, 1998, 18:5042-5051.
	D75	Olayioye, et al., "The ErbB signaling network: receptor heterodimerization in development and cancer", The EMBO Journal, 2000, 19:3159-3167.
	D76	Orlowski, et al., "NF-κB as a therapeutic target in cancer", TRENDS in Molecular Medicine, 2002, 8:385-389.
	D77	Packard BioScience, "Principles of AlphaScreen", Application Note ASC-001, 2001.
	D78	Pawson, et al., "Assembly of Cell Regulatory Systems Through Protein Interaction Domains", Science, 2003, 300:445-452
	D79	Pawson, et al., "Interaction domains: from simple binding events to complex cellular behavior", FEBS Letters, 2002, 513:2-10.
	D80	Pawson, "Specificity in Signal Transduction: From Phosphotyrosine-SH2 Domain Interactions to Complex Cellular Systems", Cell, 2004, 116:191-203.
	D81	Petricoin, et al., "Clinical Proteomics: Translating Benchside Promise Into Bedside Reality", Nature Reviews, 2002, 1:683-695.
	D82	Petricoin, et al., "Use of proteomic patterns in serum to identify ovarian cancer", The Lancet, 2002, 359:572-577
	D83	Pinkas-Kramarski, et al., "Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions", The EMBO Journal, 1996, 15:2452-2467.
	D84	Press, et al., "Evaluation of HER-2/neu Gene Amplification and Overexpression: Comparison of Frequently Used Assay Methods in a Molecularly Characterized Cohort of Breast Cancer Specimens", Journal of Clinical Oncology, 2002, 20:3095-3105.
	D85	Price, et al., "Methods for the Study of Protein-Protein Interactions in Cancer Cell Biology", Methods in Molecular Biology, 2003, 218:255-267.
	D86^	Rios, et al., "G-protein-coupled receptor dimerization: modulation of receptor function", Pharmacology & Therapeutics, 2001, 91:71-87.
	D87	Rolan, et al., "Use of biomarkers from drug discovery through clinical practice: Report of the Ninth European Federation of Pharmaceutical Sciences Conference on Optimizing Drug Development", Clinical Pharmacology & Therapeutics, 2003, 73:284-291.
	D88	Ross, et al., "The HER-2/neu Gene and Protein in Breast Cancer 2003: Biomarker and Target of Therapy", The Oncologist, 2003, 8:307-325.
	D89	Rowinsky, "Targeting Signal Transduction: The erbB Receptor Family as a Target for Therapeutic Development", Horizons in Cancer Therapeutics: From Bench to Bedside, 2:3-35 (2001)

EXAMINER	Date considered
*EXAMINER: Initial if reference considered, whether or not citation in conformance with MPEP 609; Draw line through citation if not in conformance and/or not considered. Include copy of this form with next communication to applicant.	

Form PTO-1449 (adapted)	Docket No. 131.02US	Serial No. 10/812,619
	First Named Inventor Po-Ying CHAN-HUI	Customer No. 33603
	Filing Date 30 March 2004	Group Not Yet Assigned

REFERENCES CITED BY APPLICANT

References below marked with (*) have been submitted with parent application Ser. No. 10/154,042.

References below marked with (^) have been submitted with parent application Ser. No. 10/623,057.

	D90	Sako, et al., "Single-molecule imaging of EGFR signalling on the surface of living cells", Nature Cell Biology, 2000, 2:168-172.
	D91	Schlessinger, et al., "Cell Signaling by Receptor Tyrosine Kinases", Cell, 2000, 103:211-225.
	D92^	Schlessinger, et al., "Ligand-Induced, Receptor-Mediated Dimerization and Activation of EGF Receptor", Cell, 2002, 110:669-672.
	D93	Schroeder, et al., "ErbB-β-Catenin Complexes Are Associated with Human Infiltrating Ductal Breast and Murine Mammary Tumor Virus (MMTV)-Wnt-1 and MMTV-c-Neu Transgenic Carcinomas", The Journal of Biological Chemistry, 2002, 277:22692-22698.
	D94	Schulz, et al., "Immunohistochemical Detection of Somatostatin Receptors in Human Ovarian Tumors", Gynecologic Oncology, 2002, 84:235-240.
	D95	Seymour, "Epidermal Growth Factor Receptor as a Target: Recent Developments in the Search for Effective New Anti-Cancer Agents", Current Drug Targets, 2001, 2:117-133.
	D96	Shackney, et al., "Intracellular Coexpression of Epidermal Growth Factor Receptor, Her-2/neu, and p21 ^{ras} in Human Breast Cancers: Evidence for the Existence of Distinctive Patterns of Genetic Evolution That Are Common to Tumors from Different Patients", Clinical Cancer Research, 1998, 4:913-928.
	D97	Shi, et al., "Antigen Retrieval Immunohistochemistry: Past, Present, and Future", The Journal of Histochemistry & Cytochemistry, 1997, 45:327-343.
	D98	Sidransky, "Emerging Molecular Markers of Cancer", Nature Reviews Cancer, 2002, 2:210-219.
	D99	Simon, "Receptor Tyrosine Kinases: Specific Outcomes from General Signals", Cell, 2000, 103:13-15.
	D100	Simpson, et al., "Cancer proteomics: from signaling networks to tumor markers", Trends in Biotechnology, 2001, 19:S40-S48.
	D101	Skirmisdottir, et al., "The growth factor receptors HER-2/neu and EGFR, their relationship, and their effects on the prognosis in early stage (FIGO I-II) epithelial ovarian carcinoma", Int J Gynecol Cancer, 2001, 11:119-129.
	D102	Sklar, et al., "Flow Cytometric Analysis of Ligand-Receptor Interactions and Molecular Assemblies", Annu. Rev. Biomol. Struct., 2002, 31:97-119.
	D103	Stagljär, "Finding Partners: Emerging Protein Interaction Technologies Applied to Signaling Networks", Sci. STKE, 2003, pe56:1-5.
	D104	Stancato, et al., "Fingerprinting of signal transduction pathways using a combination of anti-phosphotyrosine immunoprecipitations and two-dimensional polyacrylamide gel electrophoresis", Electrophoresis, 2001, 22:2120-2124.
	D105	Szöllösi, et al., "Applications of fluorescence resonance energy transfer for mapping biological membranes", Reviews in Molecular Biotechnology, 2002, 82:251-266.
	D106	Traxler, "Tyrosine kinases as targets in cancer therapy- successes and failures", Expert Opin. Ther. Targets, 2003, 7:215-234.
	D107	Wallasch, et al., "Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3", The EMBO Journal, 1995, 14:4267-4275.
	D108	Weng, et al., "Complexity in Biological Signaling Systems", Science, 1999, 284:92-96.

EXAMINER	Date considered
*EXAMINER: Initial if reference considered, whether or not citation in conformance with MPEP 609; Draw line through citation if not in conformance and/or not considered. Include copy of this form with next communication to applicant.	

Form PTO-1449 (adapted)	Docket No. 131.02US	Serial No. 10/812,619
REFERENCES CITED BY APPLICANT	First Named Inventor Po-Ying CHAN-HUI	Customer No. 33603
	Filing Date 30 March 2004	Group Not Yet Assigned

References below marked with (*) have been submitted with parent application Ser. No. 10/154,042.

References below marked with (^) have been submitted with parent application Ser. No. 10/623,057.

	D109	Wu, et al., "Immunofluorescent labeling of cancer marker Her2 and other cellular targets with semiconductor quantum dots", Nature Biotechnology, 2003, 21:41-46.
	D110	Xenarios, et al., "DIP: the Database of Interacting Proteins", Nucleic Acid Research, 2000, 28:289-291.
	D111	Xenarios, et al., "DIP, the Database of Interacting Proteins: a research tool for studying cellular networks of protein interactions", Nucleic Acid Research, 2002, 30:303-305.
	D112	Xenarios, et al., "Protein interaction databases", Current Opinion in Biotechnology, 2001, 12:334-339.
	D113	Xia, et al., "Combination of EGFR, HER-2/neu, and HER-3 Is a Stronger Predictor for the Outcome of Oral Squamous Cell Carcinoma Than Any Individual Family Members", Clinical Cancer Research, 1999, 5:4164-4174.
	D114	Yan, et al., "Analysis of protein interactions using fluorescence technologies", Current Opinion in Chemical Biology, 2003, 7:635-640.
	D115	Yarden, "The EGFR family and its ligands in human cancer: signalling mechanisms and therapeutic opportunities", European Journal of Cancer, 2001, 37:S3-S8.
	D116	Yarden, et al., "Untangling the ErbB Signalling Network", Molecular Cell Biology, 2001, 2:127-137.
	D117	Yarmush, et al., "Advances in Proteomic Technologies", Annu. Rev. Biomed. Eng. 2002, 4:349-373.
	D118	Yen, et al., "Differential Regulation of Tumor Angiogenesis by Distinct Erb B Homo- and Heterodimers", Molecular Biology of the Cell, 2002, 13:4029-4044.
	D119	Yu, et al., "Ligand-independent Dimer Formation of Epidermal Growth Factor Receptor (EGFR) Is a Step Separable from Ligand-induced EGFR Signaling", Molecular Biology of the Cell, 2002, 13:2547-2557.
	D120	Zhang, et al., "Transformation of NIH 3T3 Cells by HER3 or HER4 Receptors Requires the Presence of HER1 or HER2", The Journal of Biological Chemistry, 1996, 271:3884-3890.
	D121*	Fitch et al., "Improved Methods for Encoding and Decoding Dialkylamine-Encoded Combinatorial Libraries", J. Comb. Chem., 1, 1999, pgs. 188-194.
	D122*	Giese, "Electrophoretic Release Tags: Ultrasensitive Molecular Labels Providing Multiplicity", Trends in Analytical Chemistry, Vol. 2, No. 7, 1983, pgs. 166-168.
	D123^	Kochevar et al., "Photosensitized Production of Singlet Oxygen", Methods in Enzymology, Vol. 319, 2000, pgs. 20-29.
	D124*	Liu et al., "Capillary Electrochromatography-laser-induced Fluorescence Method for Separation and Detection of Dansylated Dialkylamine Tags in Encoded Combinatorial Libraries", Journal of Chromatography, Art. 924, 2001, pgs. 323-329.
	D125*	Lum et al., "Ability of Specific Monoclonal Antibodies and Conventional Antisera Conjugated to Hematoporphyrin to Label and Kill Selected Cell Lines Subsequent to Light Activation", Cancer Research, Vol. 45, 1985, pgs. 4380-4386.
	D126^	Ni et al., "Versatile Approach to Encoding Combinatorial Organic Synthesis Using Chemically Robust Secondary Amine Tags", J. Med. Chem., Vol. 39, 1996, pgs. 1601-1608.
	D127^	Olejnuk et al., "Photocleavable Affinity Tags for Isolation and Detection of Biomolecules", Methods in Enzymology, Vol. 291, 1998, pgs. 135-154.

EXAMINER	Date considered
*EXAMINER: Initial if reference considered, whether or not citation in conformance with MPEP 609; Draw line through citation if not in conformance and/or not considered. Include copy of this form with next communication to applicant.	

Form PTO-1449 (adapted)	Docket No. 131.02US	Serial No. 10/812,619
	First Named Inventor Po-Ying CHAN-HUI	Customer No. 33603
	Filing Date 30 March 2004	Group Not Yet Assigned

REFERENCES CITED BY APPLICANT

References below marked with (*) have been submitted with parent application Ser. No. 10/154,042.

References below marked with (^) have been submitted with parent application Ser. No. 10/623,057.

	D128*	Oseroff et al., "Antibody-Targeted Photolysis: Selective photodestruction of Human T-Cell Leukemia Cells Using Monoclonal Antibody-Chlorin e ₆ Conjugates", Proc. Natl. Acad. Sci. USA, Vol. 83, 1986, pgs. 8744-8748.
	D129*	Rakestraw et al., "Antibody-Targeted photolysis: <i>In vitro</i> Studies with Sn(IV) Chlorin e ₆ Covalently Bound to Monoclonal Antibodies Using a Modified Dextran Carrier", Proc. Natl. Acad. Sci. USA, Vol. 87, 1990, pgs. 4217-4221.
	D130*	Da Ros et al., "DNA-Photocleavage Agents", Current Pharmaceutical Design, Vol. 7, 2001, pgs. 1781-1821.
	D131*	Sharman et al., "Role of Activated Oxygen Species in Photodynamic Therapy", Methods in Enzymology, Vol. 319, 2000, pgs. 376-400.
	D132*	Still, "Discovery of Sequence-Selective Peptide Binding by Synthetic Receptors Using Encoded Combinatorial Libraries", Acc. Chem. Res., Vol. 29, 1996, pgs. 155-163.
	D133*	Strong, "Antibody-Targeted Photolysis", Annals New York Academy of Sciences, Vol. 745, 1994, pgs. 297-320.
	D134*	Ullman et al., "Luminescent Oxygen Channeling Immunoassay: Measurement of Particle Binding Kinetics by Chemiluminescence", Proc. Natl. Acad. Sci. USA, Vol. 91, 1994, pgs. 5426-5430.
	D135*	Yarmush et al., "Antibody Targeted Photolysis", Critical Reviews in Therapeutic Drug Carrier Systems, Vol. 10, 1993, pgs. 197-252.
	D136*	Yemul et al., "Selective Killing of T Lymphocytes by Phototoxic Liposomes", Proc. Natl. Acad. Sci. USA, Vol. 84, 1987, pgs. 246-250.
	D137	X.C. Hu et al., "Immunomagnetic Tumor Cell Enrichment is Promising in Detecting Circulating Breast Cancer Cells" Oncology, 2003;64: 160-165
	D138	Moreno et al, "Changes in Circulating Carcinoma Cells in Patients with Metastatic Prostate Cancer Correlate with Disease Status", Adult Urology, 58 (3), 2001
	D139	Zigeuner et al, "Isolation of Circulating Cancer Cells From Whole Blood by Immunomagnetic Cell Enrichment and Unenriched Immunocytochemistry in Vitro", The Journal of Urology, Vol. 169, February, 2003, 701-705
	D140	Ghossein et al., "Molecular Detection and Characterization of Circulating Tumor Cells and Micrometastases in Prostatic, Urothelial, and Renal Cell Carcinomas" Seminars in Surgical Oncology, 2001, 20: 304-311
	D141	Bong Kyung Shin, "Proteomics Approaches to Uncover the Repertoire of Circulating Biomarkers for Breast Cancer", Journal of Mammary Gland Biology and Neoplasia, Vol. 7, No. 4, Oct 2002
	D142	Emilian Racila, et al, "Detection and Characterization of Carcinoma Cells in the Blood", Proc. Natl. Acad. Sci. USA, Vol 95, pp 4589-4594, April 1998
	D143	Ivo Safarik, et al, "Use of Magnetic Techniques for the Isolation of Cells", Journal of Chromatography B., 722 (1999) 33-53
	D144^	Devi, "Heterodimerization of G-protein-coupled receptors: pharmacology, signaling and trafficking," Trends in Pharmacological Sciences, 22: 532-537 (2001)
	D145^	George et al, "G-protein-coupled receptor oligomerization and its potential for drug discovery," Nature Reviews Drug Discovery, 1: 808-820 (2002)
	D146^	Mellado et al, "Chemokine signaling and functional responses: the role of receptor dimerization and TK pathway activation," Annu. Rev. Immunol., 19: 397-421 (2001)

EXAMINER	Date considered
*EXAMINER: Initial if reference considered, whether or not citation in conformance with MPEP 609; Draw line through citation if not in conformance and/or not considered. Include copy of this form with next communication to applicant.	

Form PTO-1449 (adapted) REFERENCES CITED BY APPLICANT	Docket No. 131.02US	Serial No. 10/812,619
	First Named Inventor Po-Ying CHAN-HUI	Customer No. 33603
	Filing Date 30 March 2004	Group Not Yet Assigned

References below marked with (*) have been submitted with parent application Ser. No. 10/154,042.

References below marked with (^) have been submitted with parent application Ser. No. 10/623,057.

	D147	Rowinsky, "The ErbG Family: Targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitors," Annu. Rev. Med., 55: 433-457 (2004)
	D148	Joppich-Kuhn et al, "Release Tags: A new class of analytical reagents," Clin. Chem., 28: 1844-1847 (1982)
	D149	Bertino, "Editorial: Target Signal Transduction", Horizons in Cancer Therapeutics: From Bench to Bedside, 2: 2 (2001)
	D150^	McVey et al, "Monitoring receptor oligomerization using time-resolved fluorescence resonance energy transfer and bioluminescence resonance energy transfer," J. Biol. Chem., 276: 14092-14099 (2001)
	D151^	Gomes et al, "G Protein Coupled Receptor Dimerization: Implications in Modulating Receptor Function", J. Mol. Med., 2001, 79,, 226-242
	D152^	Salim et al, "Oligomerization of G-protein-coupled Receptors Shown by Selective Co-immunoprecipitation", Journal of Biological Chemistry, 2002, Vol. 277, No. 18, Issue of May 3, 2002, 15482-15485
	D153^	Angers et al, "Detection of β_2 -Adrenergic Receptor Dimerization in Living Cells Using Bioluminescence Resonance Energy Transfer (BRET)", PNAS, March 28, 2000, Vol. 97, No. 7, 3684-3689
	D154^	Jordan et al., "G-protein-coupled Receptor heterodimerization Modulates Receptor Function" Nature, 17 June 1999, Vol. 399, 697-700.

EXAMINER	Date considered
*EXAMINER: Initial if reference considered, whether or not citation in conformance with MPEP 609; Draw line through citation if not in conformance and/or not considered. Include copy of this form with next communication to applicant.	